Search by Drug Name or NDC

NDC 55513-0160-01 BLINCYTO Details

BLINCYTO

BLINCYTO is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amgen Inc. The primary component is .

MedlinePlus Drug Summary

Blinatumomab is used in adults and children to treat certain types of acute lymphocytic leukemia (ALL; a type of cancer of the white blood cells) that has not gotten better, or that has returned after treatment with other medications. Blinatumomab is also used in adults and children to treat ALL that is in remission (a decrease or disappearance of signs and symptoms of cancer), but some evidence of the cancer remains. Blinatumomab is in a class of medications called bispecific T-cell engager antibodies. It works by slowing or stopping the growth of cancer cells in your body.

Related Packages: 55513-0160-01
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Blinatumomab Injection

Product Information

NDC	55513-0160
Product ID	55513-160_d3375aa6-a868-417b-ac5f-d0103e470dd6
Associated GPIs	21352020002120
GCN Sequence Number	073187
GCN Sequence Number Description	blinatumomab KIT 35 MCG INTRAVEN
HIC3	V1K
HIC3 Description	ANTINEOPLASTICS ANTIBODY/ANTIBODY-DRUG COMPLEXES
GCN	37552
HICL Sequence Number	041612
HICL Sequence Number Description	BLINATUMOMAB
Brand/Generic	Brand
Proprietary Name	BLINCYTO
Proprietary Name Suffix	n/a
Non-Proprietary Name	blinatumomab
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	KIT
Route	n/a
Active Ingredient Strength	n/a
Active Ingredient Units	n/a
Substance Name	n/a
Labeler Name	Amgen Inc
Pharmaceutical Class	n/a
DEA Schedule	n/a
Marketing Category	BLA
Application Number	BLA125557
Listing Certified Through	2024-12-31

Package

NDC 55513-0160-01 (55513016001)

Pricing Information	N/A
NDC Package Code	55513-160-01
Billing NDC	55513016001
Package	1 KIT in 1 PACKAGE (55513-160-01) * 3.088 mL in 1 VIAL (55513-150-01) * 10.6 mL in 1 VIAL (55513-155-01)
Marketing Start Date	2014-12-18
NDC Exclude Flag	N